Treatment for DRESS Syndrome
Immediately discontinue the suspected culprit drug, initiate systemic corticosteroids as first-line therapy (typically oral prednisone 0.5-1 mg/kg/day or IV methylprednisolone for severe cases), and provide supportive care with close monitoring for organ involvement and viral reactivation.
Initial Management Algorithm
Step 1: Drug Withdrawal and Supportive Care
- Identify and stop all potentially causative medications immediately - this is the single most critical intervention
- Common culprits include antibiotics (vancomycin, beta-lactams, trimethoprim-sulfamethoxazole), allopurinol, and anticonvulsants 1
- Provide supportive care including fluid management, electrolyte correction, and monitoring for complications
Step 2: Severity Assessment and Corticosteroid Initiation
The treatment approach should be severity-based 2:
For Moderate to Severe DRESS:
- Start systemic corticosteroids: oral prednisone 0.5-1 mg/kg/day or IV methylprednisolone for severe cases 3, 4
- Continue for 4-6 weeks minimum with slow taper over 2-3 months to prevent relapse (which occurs in ~12% of cases) 5
- Rapid tapering is a common pitfall - premature discontinuation leads to disease flare
For Mild Cases:
- Some patients may respond to supportive care alone, but close monitoring is essential
- Low threshold to initiate corticosteroids if progression occurs
Step 3: Monitor for Complications
Key monitoring parameters include:
- Organ involvement: Liver function tests (most common), renal function, cardiac enzymes (eosinophilia severity correlates with cardiac involvement) 3
- Viral reactivation: Check for HHV-6, CMV, EBV reactivation during treatment 4
- Eosinophil counts and eosinophil cationic protein levels 3
Second-Line and Steroid-Sparing Options
For Steroid-Resistant or Steroid-Dependent DRESS:
Cyclosporine:
Intravenous Immunoglobulin (IVIG):
IL-5 Axis Inhibitors (Novel Approach):
- Benralizumab (anti-IL-5 receptor): Single dose often sufficient for clinical resolution 8
- Mepolizumab (anti-IL-5): Multiple doses typically needed 8
- These biologics show promise for steroid-resistant cases or patients prone to corticosteroid toxicity, given the central role of eosinophils in DRESS pathogenesis 8
Plasmapheresis:
Critical Caveats and Pitfalls
Timing of Skin Testing
- Do not perform patch testing or delayed intradermal testing until ≥6 months after acute reaction AND patient has been off systemic corticosteroids for ≥1 month 5
- Patch test sensitivity for DRESS is 64%, but premature testing has lower sensitivity and risks HHV reactivation 5
- Even with negative testing, never rechallenge with the culprit drug - the negative predictive value is insufficient 5
Relapse Risk
- 12% relapse rate, typically occurring during corticosteroid taper 5
- Maintain vigilance for 2-3 months after initial presentation
Pediatric Considerations
- Children may present differently than adults with variations in clinical features, prognosis, and mortality 2
- No validated pediatric-specific diagnostic criteria exist; adult criteria are extrapolated 2
- Severity-based treatment approach should be adapted to pediatric needs 2
Age as Prognostic Factor
- Older patients may have poorer outcomes even with lower RegiSCAR scores - age should factor into severity assessment 3
Long-Term Management
- Taper corticosteroids slowly over 2-3 months minimum
- Monitor for late complications including autoimmune sequelae
- Document culprit drug clearly in medical records with allergy alerts
- Counsel patients on cross-reactivity patterns and avoidance strategies
The evidence base for DRESS treatment remains limited, with only case series and expert consensus available 2. However, the combination of immediate drug withdrawal and systemic corticosteroids represents the standard of care, with emerging biologics offering hope for difficult cases 6, 8.